Consequently, RIPK1 is an attractive therapeutic target and several clinical trials are currently underway to investigate the efficacy of RIPK1 inhibitors, after successfully completing the safety clinical phase, in patients with rheumatoid arthritis, acute graft-versus-host disease, cardiac surgery-associated acute kidney injury, or ulcerative colitis ([7] and data collected from clinicaltrials.gov). The gene discussed is RIPK1; the disease is rheumatoid arthritis.